Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Axsome Therapeutics ( (AXSM) ) has shared an announcement.
On November 3, 2025, Axsome Therapeutics reported a significant 63% year-over-year growth in net product revenue for the third quarter of 2025, totaling $171 million. The company also submitted a supplemental NDA for AXS-05 for Alzheimer’s disease agitation, highlighting its strong commercial performance and pipeline progress. The financial results reflect robust sales of AUVELITY, SUNOSI, and the newly launched SYMBRAVO, positioning Axsome for continued growth and innovation in the CNS disorder treatment market.
The most recent analyst rating on (AXSM) stock is a Hold with a $136.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
Spark’s Take on AXSM Stock
According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.
Axsome Therapeutics demonstrates strong revenue growth and positive technical momentum, which are key strengths. However, significant profitability challenges, high leverage, and a negative P/E ratio weigh on the overall score. The earnings call provided a positive outlook, but market access issues for new products and high net losses remain concerns.
To see Spark’s full report on AXSM stock, click here.
More about Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company offers products such as AUVELITY, SUNOSI, and SYMBRAVO, targeting major depressive disorder, excessive daytime sleepiness, and migraines, respectively.
Average Trading Volume: 521,438
Technical Sentiment Signal: Buy
Current Market Cap: $6.74B
Learn more about AXSM stock on TipRanks’ Stock Analysis page.